Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.
about
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implicationsEvaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineHigh frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virusThe roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolismCardiovascular Complications of HIV in Endemic Countries.Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.Hyperlipidemia associated with protease inhibitor therapy.Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.Infection and inflammation-induced proatherogenic changes of lipoproteins.Prevalence of metabolic syndrome in human immunodeficiency virus - infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria.Glucose disorders associated with HIV and its drug therapy.Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review.Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast.Nutrition and HIV infection.Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders.HIV and HAART-Associated DyslipidemiaDyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, TanzaniaClinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsFasting Triglyceride Concentrations are Associated with Early Mortality Following Antiretroviral Therapy in Zambia.Lipodystrophy in HIV patients: its challenges and management approaches.The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients.Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Coronary heart disease in HIV-infected patients.Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu miceSafety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.Minocycline- and tetracycline-induced hypertriglyceridemia in an HIV-seropositive patient receiving combination antiretroviral therapy.State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summaryThe management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review.Hormonal contraception and HIV-positive women: metabolic concerns and management strategiesNew options in the treatment of lipid disorders in HIV-infected patients.A Study to Evaluate Lipid Profile in Treatment Naïve HIV Positive Patients.Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.Nutrition support and the human immunodeficiency virus (HIV).Endotoxin, cytokines, and hyperlipidemia.TNF and AIDS: two sides of the same coin?Rhabdomyolysis: a case study exploring the possible side effect of lipid lowering medication by a HIV positive patient taking a protease inhibitor.The relationship of serum total sialic acid with serum acute phase proteins and lipoprotein (a) in patients with severe hypertriglyceridaemia.HIV wasting syndrome: treatment update.
P2860
Q24598812-982227EB-D06B-4749-8717-C861F22B4730Q24608464-3A97885F-8C37-44E4-9F07-00E7C22B0A19Q24814179-78A1C551-BD2D-4566-9D9C-EA53AB25D2FCQ27021950-C206FE5B-78A6-44F2-9443-D0FC74370886Q30244655-4024C2ED-18A4-4BD4-8B43-029157FBE641Q33639909-13C83010-9E7D-4C06-A232-9571D16607B2Q33722497-1F425645-9977-470C-A436-6301FA4F108BQ33926941-B8549EBA-C008-43E9-8259-C1F73DE2BFE2Q33935040-E7BD1527-0A27-4294-9380-904CEF4269ECQ34136175-A5E6EE71-7CE7-4285-BD8A-17CB3C69910CQ34191314-14063212-808E-48FC-BCBD-47BBB0E40AF5Q34397028-0C966CFF-02A6-4365-ACD7-B56C2A784A0DQ34474725-E914CA0D-E4E1-4AC1-89FC-2EFE2414AD1FQ34564488-1BE1C47C-0B68-407F-904D-C2E833E34420Q34570634-D141772C-EEEC-46F3-85BC-7BAFBB8345E0Q35020217-6B2F7720-7748-4A06-821D-98359CF8FE33Q35074678-43BB9186-E67D-49E8-B78F-01378A9FAB98Q35175902-FC5AA282-79D4-46F6-B014-9BD12BF3EF30Q35206635-21722B2A-7D64-4854-8886-F779740E4020Q35513728-822AC425-84C9-4A6F-AAC5-8CBE6C06238BQ35671755-32ADB455-E099-47FC-84FC-1F15B8AFACFDQ35946036-39226811-B213-4D80-AB03-8A89D677B4B7Q35960732-65A44F19-DAD8-4EAB-97FB-7AA412AFAB4AQ36158019-9C48211D-EB33-4840-A5EC-37E0E5971825Q36223870-DC750A54-ECBE-4CEC-B48D-A3C594A3AF96Q36363956-868F4D92-BAD0-4502-B2A3-E19F50D86935Q36528526-E0E5DCFE-3B2A-4DCC-B01B-689B0A7D9821Q36714593-D00D474E-E66D-4D59-8255-4D40622A53EEQ36812073-3BECE2EA-8DAD-4355-8215-A3D865E718BBQ36895939-8A377122-A122-41E1-A1ED-80C398AAA34AQ37202281-BBC82E11-F5D0-4992-AE03-EC814B0379CAQ37271807-C81561C3-7E79-45D1-BCBF-8EC92649F819Q37521981-35F45C36-7BBA-45FB-9AA9-063BBB8B4504Q39808046-753FE4EB-32D9-4E1F-86C1-E0EB64DA6B96Q40718124-05B813FB-C607-4737-80A1-53EC46EF09BEQ40851762-4D3C530C-76FB-4A7C-9420-03BC67EBEB5BQ40943847-68F0108F-D9C1-486B-AB28-6C41E5CBBEDFQ41113376-FC2A7618-5467-4D9D-8441-3223BE8E75F2Q41662348-35674C41-ADCB-4127-869A-B427708AE769Q41751382-4B9E8090-B7BA-4E3E-9E15-4DD212649DEA
P2860
Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Circulating interferon-alpha l ...... red immunodeficiency syndrome.
@en
Circulating interferon-alpha l ...... red immunodeficiency syndrome.
@nl
type
label
Circulating interferon-alpha l ...... red immunodeficiency syndrome.
@en
Circulating interferon-alpha l ...... red immunodeficiency syndrome.
@nl
prefLabel
Circulating interferon-alpha l ...... red immunodeficiency syndrome.
@en
Circulating interferon-alpha l ...... red immunodeficiency syndrome.
@nl
P2093
P1476
Circulating interferon-alpha l ...... red immunodeficiency syndrome.
@en
P2093
C Grunfeld
D P Kotler
J K Shigenaga
K R Feingold
R N Pierson
W Doerrler
P304
P356
10.1016/0002-9343(91)80154-E
P407
P577
1991-02-01T00:00:00Z